上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
SR-4835 纯度: 99.82%
SR-4835 是有效,高选择性和 ATP 竞争性的 CDK12/CDK13 双重抑制剂 (CDK12:IC50=99 nM,Kd=98 nM;CDK13:Kd=4.9 nM)。SR-4835 与破坏 DNA 的化学疗法和 PARP 抑制剂协同作用,并引起三阴性乳腺癌 (TNBC) 细胞凋亡。
SR-4835 Chemical Structure
CAS No. : 2387704-62-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1650 | In-stock | |
5 mg | ¥1500 | In-stock | |
10 mg | ¥2500 | In-stock | |
25 mg | ¥5000 | In-stock | |
50 mg | ¥7800 | In-stock | |
100 mg | ¥11500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
SR-4835 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Cell Cycle/DNA Damage Compound Library
- Kinase Inhibitor Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Anti-Breast Cancer Compound Library
- Anti-Blood Cancer Compound Library
- Targeted Diversity Library
生物活性 |
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
SR-4835 (90 nM; 0.5-48 hours) suppresses ATM and RAD51 protein levels[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
|
||||||||||||||||
分子量 |
499.36 |
||||||||||||||||
Formula |
C21H20Cl2N10O |
||||||||||||||||
CAS 号 |
2387704-62-1 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 8.93 mg/mL (17.88 mM; ultrasonic and warming and heat to 60°C) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务